Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01864226
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Drug: PlaceboRadiation: RadiotherapyDrug: SOC Agent
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 296
- Registration Number
- NCT01860638
- Locations
- 🇦🇹
Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria
🇷🇴Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria
An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)
- Conditions
- Hepatitis D, Chronic
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01861444
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 718
- Registration Number
- NCT01855789
- Locations
- 🇺🇸
Phase Iii Clinical Research, Fall River, Massachusetts, United States
🇺🇸Fort Smith Rheumatology, PC, Fort Smith, Arkansas, United States
🇺🇸Joao Nascimento, Bridgeport, Connecticut, United States
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1669
- Registration Number
- NCT01855997
- Locations
- 🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie, Wien, Austria
🇨🇳The First Affiliate Hospital of Guangxi Medical University, Nanning, China
🇨🇳Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT01853254
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
- Conditions
- Malignant Melanoma, Neoplasms
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01851824
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
- Conditions
- Malignant Melanoma, Neoplasms
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01849666
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
- Conditions
- Malignant Melanoma, Neoplasms
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01844674
- Locations
- 🇨🇾
Bank of Cyprus Oncology Center, Nicosia, Cyprus
🇨🇦CSSS champlain - Charles-Le Moyne, Greenfield Park, Quebec, Canada
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1600
- Registration Number
- NCT01839500
- Locations
- 🇨🇳
Anyang Tumor Hosptial, Anyang, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China